ArticleThe International journal of eating disorders2025
Mirtazapine Is Associated With Shorter Hospital Stay in Pediatric Avoidant Restrictive Food Intake Disorder-A Retrospective Chart Review.
Article in The International journal of eating disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Disorders of Gut-Brain Interaction in Eating Disorders: A Review of Management Approaches.Current psychiatry reports · 2026Review
- Mirtazapine Is Associated With Shorter Hospital Stay in Pediatric Avoidant Restrictive Food Intake Disorder-A Retrospective Chart Review.The International journal of eating disorders · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAvoidant restrictive food intake disorder (ARFID) is a relatively new diagnostic entity, and no medication has been approved. Recent data suggest that mirtazapine, a tetracyclic antidepressant, could improve outcomes in ARFID. We conducted a retrospective chart review to examine the effects of mirtazapine on ARFID treatment in youth.
methodsHospital records from 87 children and adolescents with ARFID treated in an inpatient medical stabilization program were analyzed. Treatment outcome was tested for the effects of mirtazapine on weight gain, length of hospitalization, and duration of nasogastric feeding tube versus orally delivered nutrition. Other medications prescribed (selective serotonin reuptake inhibitors, dopamine D2 receptor partial agonist aripiprazole, and dopamine D2 receptor antagonists) and comorbid disorders (depression and anxiety) were included in the analysis.
resultsAge was similar between individuals treated with or without mirtazapine (12.7 ± 1.0 years vs. 13.1 ± 1.0 years). Thirty-eight (44%) patients with ARFID were treated with mirtazapine. MANOVA indicated significant effects of mirtazapine (Wilks' λ = 0.741, F = 3.322, p = 0.007, partial η DISCUSSION: In our highly controlled environment, all patients reached a comparable target weight, but patients treated with mirtazapine did so faster. Further research should investigate the clinical effects and underlying mechanisms of mirtazapine in patients with ARFID.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.